Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source
Thymosin Beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.
PloS one · 2014
Study scale: A total of six mice were studied in each group.
Abstract only: Open source record
Product or molecular entity relationships
- Thymosin Beta-4 (TB500): Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Investigating a key molecule is required for development of new therapeutic intervention.
Study design
In monocrotaline (MCT)-induced PH mouse model, we showed that mice treated with Tβ4 significantly attenuated the systolic pressure and RVH, compared to the MCT treated mice.
Participants or experimental system
The pathology of PAH involves vascular cell remodeling including pulmonary arterial endothelial cell (PAEC) dysfunction and pulmonary arterial smooth muscle cell (PASMC) proliferation.
Study scale
A total of six mice were studied in each group.
Intervention or exposure
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Comparator
Age- and sex-matched WT with normal saline-injected mice of C57BL/6 background served as controls.
Outcomes examined
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Key findings
As a result there is an increase in pulmonary vascular resistance and pulmonary arterial pressure causing right ventricular hypertrophy (RVH) and RV failure.
Limitations and uncertainty
Current therapies are limited to reverse the vascular remodeling.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.